[Prevention of liver fibrosis and liver cancer linked to hepatitis B virus in Africa: the Prolifica study]

Med Sci (Paris). 2019 May;35(5):431-439. doi: 10.1051/medsci/2019076. Epub 2019 May 22.
[Article in French]


Despite the existence of an effective vaccine, HBV infects 257 million people worldwide and is the cause of the majority of HCC. With an annual mortality rate of 887 000 patients in 2015, this cancer is the second deadliest. Low-income countries such as ones in sub-Saharan Africa are the most at risk due to the limited access to healthcare. To overcome this and born from an international research collaboration within an EU project, the Prolifica study aimed at evaluating a screen-and-treat program to prevent HBV complications, and more particularly HCC. Based on communities, facilities and hospitals HBsAg+ detection, the study lasted from 2011 to 2016. From the "cost effectiveness" feasibility of such a program to the development of simple scores for antiviral treatment, Prolifica uncovered data of crucial importance in a region with low HBV infection awareness, transmissions modes and prevention means which could have impacts on public health policies.

Publication types

  • Review

MeSH terms

  • Africa South of the Sahara
  • Health Policy
  • Health Services Accessibility / statistics & numerical data
  • Hepatitis B / complications*
  • Hepatitis B / diagnosis
  • Hepatitis B / prevention & control
  • Hepatitis B Surface Antigens / blood
  • Humans
  • Liver Cirrhosis / prevention & control*
  • Liver Cirrhosis / virology*
  • Liver Neoplasms / prevention & control*
  • Liver Neoplasms / virology*
  • Poverty


  • Hepatitis B Surface Antigens